| Nov 19 |
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
|
| Nov 12 |
ImmunityBio Non-GAAP EPS of -$0.14 beats by $0.04, revenue of $6.1M beats by $3.18M
|
| Nov 12 |
ImmunityBio Reports Third-Quarter 2024 Financial Results
|
| Oct 28 |
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
|
| Oct 28 |
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
|
| Oct 28 |
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Oct 27 |
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
|
| Oct 25 |
ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
|
| Oct 25 |
ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
|
| Oct 25 |
ImmunityBio extends gains after trial update
|
